Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CRVO
CRVO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRVO News
CervoMed Advances Neflamapimod in Phase 3 Trial for Dementia
6d ago
Newsfilter
CervoMed's Neflamapimod Approved for ALS Trials
Feb 18 2026
Newsfilter
Biotech Insider Buying Signals Strong, Three Companies Draw Attention
Jan 15 2026
Benzinga
CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial
Dec 04 2025
Globenewswire
CervoMed Reports New Data on Neflamapimod Clinical Trial, Significant GFAP Reduction
Dec 02 2025
Globenewswire
CervoMed's Neflamapimod Significantly Reduces Neurodegeneration Biomarker GFAP
Dec 02 2025
Newsfilter
CervoMed Inc. (CRVO) Announces Q3 Loss and Falls Short of Revenue Projections
Nov 08 2025
NASDAQ.COM
Docebo Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Wednesday
Nov 05 2025
Benzinga
Trex Company Analyst Adopts Bearish Stance; Check Out Wednesday's Top 5 Downgrades
Nov 05 2025
Benzinga
Sarepta Therapeutics Analyst Becomes Optimistic; Check Out Wednesday's Top 5 Upgrades
Nov 05 2025
Benzinga
HC Wainwright & Co. Boosts CervoMed Rating to Buy and Increases Price Target to $25
Nov 05 2025
Benzinga
D. Boral Capital Reiterates Buy Rating on CervoMed with $31 Price Target Intact
Nov 04 2025
Benzinga
Join the Live Stream of Day 1 at the Emerging Growth Conference 87 on October 22. Register Now!
Oct 20 2025
Globenewswire
CervoMed to Showcase at the Emerging Growth Conference
Oct 20 2025
Newsfilter
CervoMed Reveals New Phase 2b Trial Data Highlighting Neflamapimod's Promise for Treating Dementia with Lewy Bodies
Oct 08 2025
Newsfilter
CervoMed Showcases Neflamapimod's Promising Advantages for Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
Sep 17 2025
Newsfilter
Show More News
